Stocks Health care CUE
NASDAQ · Health careCue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. brought in $37.7M of revenue over the twelve months to June 30, 2026, up 354.4% from a year earlier. It posted a net loss of $164.1M. In fiscal 2025 capital spending exceeded operating cash flow by $21.9M. At June 30, 2026 it held $17.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Cue Biopharma, Inc. does
Cue Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CUE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $27.5M | -$26.6M | -$0.28 | -$21.9M |
| 2024 | $9.3M | -$40.7M | -$0.72 | -$36.4M |
| 2023 | $5.5M | -$50.7M | -$1.11 | -$40M |
| 2022 | $1.2M | -$53M | -$1.49 | -$42M |
| 2021 | $14.9M | -$44.2M | -$1.41 | -$39.8M |
| 2020 | $3.2M | -$44.8M | -$1.56 | -$33.1M |
Where CUE ranks in Health care
Latest SEC filings
What Cue Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026
- August 21, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026
- August 14, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 3, 2026
- July 10, 2026
- June 18, 2026
- June 3, 2026
Insider trades
What the people running Cue Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 9, 2026 | Garzone PamelaDirector | Received as pay | 18,900 | - |
| July 9, 2026 | Sarraf PashaDirector | Received as pay | 18,400 | - |
Questions about CUE
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CUE.
Is Cue Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $164.1M on revenue of $37.7M.
How much revenue does Cue Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Cue Biopharma, Inc. reported revenue of $37.7M. That is 354.4% more than a year earlier.
When did Cue Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 21, 2026.
Similar companies
Compare CUE with
Follow CUE
Get an email when Cue Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CUE: get an email when it filesWhere the numbers come from
Financial figures are the values Cue Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.